vaccin
effici
tool
prevent
diseas
caus
infecti
pathogen
tuberculosi
tb
remain
major
world
health
problem
million
new
case
million
death
per
year
current
vaccin
bovi
bcg
display
variabl
protect
human
new
tb
vaccin
urgent
although
genet
engin
allow
develop
recombin
protein
larg
scale
vaccin
antigen
alon
gener
insuffici
elicit
protect
immun
respons
adjuv
requir
enhanc
antigenspecif
immun
respons
although
mani
case
mechan
adjuv
action
still
well
major
challeng
achiev
potent
adjuv
effect
avoid
reactogen
toxic
unfortun
potent
adjuv
typic
associ
greatest
local
system
toxic
eg
complet
freund
therebi
larg
preclud
use
particularli
prophylact
vaccin
set
ideal
addit
safe
well
toler
adjuv
promot
appropri
humor
andor
cellular
immun
respons
long
shelflif
stabl
biodegrad
cheap
produc
limit
number
adjuv
formul
test
clinic
trial
tb
subunit
vaccin
candid
adjuv
typic
complex
multicompon
formul
select
abil
induc
respons
usual
measur
product
antigenspecif
cell
similar
propos
mode
action
exampl
immunomodulatori
molecul
mpl
monophosphoryl
lipid
mpl
synthet
analogu
glucopyranosyl
lipid
adjuv
gla
mycobacteri
cell
wall
compon
trehalos
dimycol
tdm
part
inflammatori
adjuv
initi
respons
pattern
recognit
receptor
tolllik
receptor
tlr
mpl
deriv
macrophag
induc
lectin
mincl
tdm
oligonucleotid
compon
adjuv
act
similarli
activ
nfkb
result
proinflammatori
cytokin
current
studi
adjuvant
novel
polysaccharid
adjuv
call
assess
murin
model
virul
tuberculosi
infect
advax
made
semicrystallin
delta
inulin
polysaccharid
particl
approxim
micron
advax
shown
wide
rang
anim
model
enhanc
vaccin
immunogen
protect
pathogen
includ
japanes
enceph
west
nile
hepat
b
sar
listeria
monocytogen
bacillu
anthraci
well
noninfecti
diseas
alzheim
mice
advax
gener
protect
immun
reduc
local
inflamm
compar
alum
importantli
advax
adjuv
shown
safe
effect
human
trial
hepat
vaccin
therebi
significantli
derisk
use
tb
vaccin
develop
studi
formul
advax
adjuv
alon
combin
cpg
oligonucleotid
combin
fusion
assess
abil
protect
virul
tuberculosi
infect
togeth
mechanist
studi
impact
advaxcontain
vaccin
innat
adapt
immun
respons
fusion
protein
compris
tuberculosi
cysd
antigen
previous
found
provid
protect
immun
pulmonari
tuberculosi
challeng
mice
formul
mpl
combin
dimethyldioctadecylammonium
dda
high
adjuvant
mpl
report
highli
adequ
stimul
longterm
cell
concern
mpldda
toxic
make
combin
unsuit
human
use
necess
identifi
altern
safe
effect
human
adjuv
advanc
human
trial
advax
adjuv
prove
safe
well
toler
human
influenza
henc
sought
test
abil
enhanc
protect
immun
mice
vaccin
intramuscularli
im
dose
incorpor
cpg
advaxcpg
immunogen
assess
examin
respons
peripher
blood
mononuclear
cell
pbmc
week
last
vaccin
group
show
high
frequenc
tripl
posit
doubl
posit
produc
cell
antigenstimul
pbmc
fig
b
contrast
level
polyfunct
cell
induc
much
lower
fig
examin
frequenc
cell
elispot
demonstr
induc
compar
respons
fig
product
detect
pbmc
mice
vaccin
either
formul
data
shown
togeth
result
show
vaccin
lesser
extent
induc
vaccinespecif
respons
consid
respons
elicit
advaxadjuv
vaccin
next
determin
could
afford
protect
low
dose
aerosol
challeng
virul
tuberculosi
vaccin
mice
bcg
result
approxim
reduct
lung
tuberculosi
cfu
count
compar
unvaccin
mice
differ
statist
signific
fig
induc
greatest
level
protect
although
significantli
greater
seen
mice
protect
afford
equival
observ
bcg
fig
lung
unvaccin
mice
characteris
larg
unorganis
area
inflammatori
infiltr
mostli
compos
cell
larg
amount
cytoplasm
like
macrophag
see
supplementari
fig
lung
bcgvaccin
mice
gener
less
tissu
involv
smaller
lesion
macrophagelik
cell
high
number
lymphocyt
lung
anim
demonstr
reduc
cellular
infiltr
organis
characteris
presenc
higher
number
lymphocyt
compar
unvaccin
group
result
indic
formul
advax
adjuv
formul
reduc
pulmonari
bacteri
load
infectioninduc
patholog
mice
challeng
aerosolis
tuberculosi
next
look
pattern
postchalleng
immun
respons
correl
protect
advaxvaccin
mice
initi
determin
cytokinereleas
cell
taken
mice
day
postchalleng
stimul
ex
vivo
individu
protein
compon
cysd
highest
level
product
observ
upon
restimul
cell
anim
fig
respons
next
highest
cell
anim
higher
level
unvaccin
mice
fig
correl
gener
pattern
observ
prechalleng
cytokin
profil
fig
restimul
cysd
protein
induc
lower
level
releas
highest
respons
measur
vaccin
group
fig
tnf
releas
low
pgml
rang
group
nevertheless
increas
mice
fig
increas
product
detect
group
fig
characteris
immun
postchalleng
frequenc
antigenspecif
multicytokinesecret
cell
compar
group
mice
highest
frequenc
multifunct
cell
fig
similar
profil
observ
mice
albeit
lower
frequenc
expans
multifunct
cell
statist
differ
observ
unvaccin
bcgvaccin
mice
frequenc
singlecytokinesecret
cell
particularli
secret
pronounc
fig
result
demonstr
lesser
extent
elicit
gener
multifunct
cell
frequenc
correl
level
protect
afford
tuberculosi
challeng
next
investig
possibl
advax
adjuv
may
potenti
vaccin
protect
enhanc
recruit
immun
cell
site
immunis
mice
inject
id
ear
advax
formul
pb
control
without
antigen
allow
quantif
cell
recruit
site
rout
vaccin
shown
induc
similar
immunogen
postchalleng
tuberculosi
equival
level
protect
previous
observ
im
rout
see
supplementari
fig
leukocyt
composit
skin
site
inject
determin
day
use
gate
strategi
shown
supplementari
fig
local
accumul
neutrophil
cell
fig
macrophagesmonocyt
fig
e
observ
day
inject
advax
advaxcpg
advaxcpg
induc
greatest
chemotaxi
higher
frequenc
neutrophil
macrophagesmonocyt
compar
advax
alon
fig
e
interestingli
increas
observ
within
popul
within
subset
inflammatori
subset
may
differenti
inflammatori
howev
appar
differ
frequenc
convent
dc
group
observ
time
point
examin
mhciihi
fig
f
investig
possibl
immun
mediat
immun
cell
recruit
measur
level
cytokineschemokin
ear
cell
cultur
cell
mice
vaccin
advax
advaxcpg
exhibit
higher
level
neutrophil
attract
compar
pbsinject
mice
fig
cellular
recruit
also
correl
higher
level
fig
tnf
fig
data
shown
pronounc
advaxcpginject
mice
contrast
detect
consid
potent
abil
advaxcpg
recruit
immun
cell
subset
inject
site
abil
drive
prime
antigenspecif
cell
next
assess
cfselabel
splenocyt
mice
whose
cell
recognis
tuberculosi
protein
adopt
transfer
mice
vaccin
id
alon
advaxcpg
day
postimmunis
cfselabel
cell
start
prolifer
auricular
lymph
node
aln
group
prolifer
pronounc
mice
immunis
fig
earli
timepoint
total
number
cell
significantli
greater
compar
pbsvaccin
mice
fig
day
postimmunis
divis
cfselabel
cell
aln
start
seen
alon
group
fig
higher
number
prolifer
cell
group
fig
furthermor
analysi
cytokin
releas
cell
peptid
restimul
reveal
high
proport
cell
advaxcpgvaccin
anim
display
tripl
posit
phenotyp
follow
doubleposit
cell
produc
either
fig
contrast
mice
vaccin
alon
advaxcpg
alon
pb
exhibit
mainli
tnf
cell
although
alon
group
also
exhibit
signific
proport
doubl
posit
cell
fig
thu
advaxcpg
potent
chemotact
agent
stimul
earli
prime
expans
antigenspecif
cell
immunis
site
promot
multipot
cell
subset
limit
number
adjuv
current
licens
use
human
vaccin
eg
aluminumbas
salt
squalenebas
emuls
rel
poor
induc
type
consequ
identif
adjuv
use
tb
vaccin
human
major
unresolv
challeng
critic
progress
vaccin
studi
assess
capac
advax
delta
inulinbas
adjuv
induc
protect
cellular
immun
tuberculosi
infect
advax
adjuv
use
induc
protect
immun
wide
rang
pathogen
across
multipl
anim
speci
importantli
alreadi
shown
welltoler
immunogen
human
report
demonstr
first
time
advax
adjuv
formul
fusion
protein
confer
protect
aerosol
challeng
tuberculosi
fig
level
protect
induc
advaxadjuv
vaccin
rang
cfu
reduct
compar
unvaccin
mice
similar
seen
preclin
studi
tb
vaccin
candid
enter
clinic
trial
exampl
notabl
advax
alon
singl
compon
adjuv
could
provid
signific
protect
tuberculosi
adjuv
use
complex
requir
multipl
compon
achiev
protect
effect
identif
advax
novel
antigen
protect
broad
array
pathogen
includ
tb
complement
recent
report
demonstr
differ
adjuv
display
distinct
immunolog
signatur
independ
vaccin
addit
cpg
advax
advaxcpg
improv
protect
similar
result
cpg
ad
tb
candid
enhanc
protect
addit
cpg
advax
previous
seen
vaccin
sar
japanes
enceph
west
nile
viru
pandem
avian
influenza
suggest
synergist
protect
observ
current
studi
two
adjuv
compon
wide
generaliz
phenomenon
base
benefici
effect
human
phase
vaccin
trial
involv
advaxcpg
adjuv
current
underway
petrovski
et
al
unpublish
observ
mechan
wherebi
cpg
synergis
delta
inulin
compon
advax
current
investig
shown
use
advaxcpg
particularli
associ
increas
frequenc
tripleposit
cell
greater
chemotaxi
immun
cell
inject
site
advax
alon
suggest
addit
cpg
advax
help
drive
greater
chemotaxi
stronger
effector
memori
cell
respons
analysi
pre
postinfect
immun
respons
reveal
combin
either
advax
formul
elicit
vaccinespecif
respons
greater
one
elicit
bcg
vaccin
fig
abil
advax
induc
strong
recal
respons
antigenspecif
cell
also
seen
hepat
immunis
model
amongst
other
analysi
cytokin
secret
show
advax
formul
success
induc
polyfunct
cell
induc
appreci
level
tripleposit
cell
pre
postchalleng
higher
induc
bcg
unvaccin
level
polyfunct
cell
shown
correl
better
protect
numer
model
infect
includ
particular
suggest
optim
tb
protect
achiev
gener
pool
tripleposit
multifunct
cell
mediat
rapid
effector
vaccin
mice
doubl
posit
cell
subset
observ
characterist
central
memori
cell
high
prolif
capac
correl
protect
efficaci
tb
vaccin
candid
howev
studi
presenc
polyfunct
cell
either
bcgvaccin
correl
protect
tb
human
highlight
incomplet
understand
immun
correl
vaccineinduc
tb
protect
respons
thought
contribut
protect
mycobacteri
infect
trigger
express
chemokin
lung
turn
may
mediat
recruit
protect
cell
howev
advaxadjuv
vaccin
formul
afford
signific
protect
infect
without
induc
detect
level
fig
notabl
may
doubleedg
sword
excess
associ
heighten
inflamm
tissu
damag
mycobacteri
henc
adjuv
advax
primarili
induc
multifunct
respons
rather
domin
respons
may
repres
safer
candid
human
tb
vaccin
use
local
respons
induc
adjuv
site
inject
repres
first
seri
event
lead
protect
immun
respons
characteris
number
experiment
adjuv
includ
studi
show
inject
advax
formul
induc
chemoattractantscytokin
tnf
may
respons
observ
rapid
influx
neutrophil
monocytesmacrophag
site
vaccin
fig
innat
cell
popul
interact
complex
microenviron
distinct
role
popul
individu
contribut
effect
vaccineinduc
immun
complet
exampl
neutrophil
rapidli
internalis
mycobacteria
particip
initi
adapt
immun
supress
releas
inflammatori
cytokin
suppress
neutrophil
apoptosi
appear
strategi
use
tuberculosi
delay
activ
adjuvantinduc
neutrophil
shown
regul
level
antigen
present
dc
henc
neutrophil
attract
site
immun
advax
adjuv
may
assist
enhanc
antigen
present
local
tcell
activ
howev
role
neutrophil
protect
immun
tb
complex
excess
neutrophil
infiltr
tuberculosi
infect
mous
associ
increas
lung
patholog
pronounc
suscept
also
observ
recruit
larg
number
monocytesmacrophag
fig
particular
monocytesmacrophag
subset
shown
abl
differenti
dc
migrat
drain
ln
facilit
antigen
inde
observ
singl
dose
formul
advaxcpg
induc
signific
recruit
local
prime
vaccinespecif
cell
result
gener
polyfunct
cell
secret
multipl
effector
cytokin
drain
ln
fig
support
role
advax
adjuv
induc
local
inject
site
chemotact
signal
recruit
antigen
present
cell
site
immunis
lead
enhanc
antigen
present
activ
expans
memori
cell
upon
inject
advax
particl
rapidli
endocytos
dendrit
cell
dc
although
specif
receptor
mediat
process
still
unknown
petrovski
et
al
unpublish
observ
delta
inulin
retain
adjuv
action
doubl
knockout
mice
indic
requir
tlr
signal
action
petrovski
et
al
unpublish
observ
howev
studi
requir
determin
cell
subset
directli
involv
advax
uptak
cell
prime
antigenload
apc
refractori
cell
stimul
mycobacteri
time
antigen
adjuv
deliveri
apc
critic
induct
cell
like
neutrophil
monocytemacrophag
accumul
deleteri
effect
mycobacteri
therefor
level
myeloid
cell
recruit
induc
vaccin
recal
respons
may
critic
balanc
effect
immun
immunopatholog
reassuringli
evid
local
system
toxic
either
pre
postchalleng
mice
receiv
immunis
support
safeti
toler
data
advax
adjuv
seen
recent
human
conclus
result
present
demonstr
advax
adjuv
incorpor
tb
subunit
vaccin
confer
strong
immunogen
protect
tuberculosi
mous
model
effect
enhanc
addit
cpg
compon
potenti
immun
cell
recruit
subsequ
multifunct
effector
cell
respons
consid
accept
safeti
toler
profil
advax
combin
strong
candid
preclin
evalu
progress
human
trial
tuberculosi
bovi
bcg
pasteur
grown
middlebrook
medium
bd
supplement
glycerol
tyloxapol
albumindextrosecatalas
adc
solid
middlebrook
medium
bd
supplement
oleic
protein
antigen
cysd
produc
recombin
form
eschericia
coli
describ
antigen
puriti
assess
sd
page
analysi
absenc
contamin
e
coli
protein
vaccin
demonstr
lack
cytokin
releas
cell
mice
restimul
irrelev
recombin
mycobacteri
protein
produc
methodolog
see
supplementari
fig
peptid
synthetis
genescript
advax
advaxcpg
provid
vaxin
pti
ltd
adelaid
south
australia
femal
week
age
purchas
anim
resourc
centr
perth
australia
mice
maintain
specif
pathogenfre
condit
experi
perform
approv
sydney
local
health
district
anim
welfar
committe
approv
number
accord
relev
guidelin
regul
anim
randomli
assign
experiment
group
protect
experi
mice
vaccin
subcutan
sc
base
tail
either
cfu
bcg
pasteur
pb
im
time
week
interv
recombin
protein
formul
advax
advaxcpg
mg
delta
inulin
per
dose
without
mer
type
b
oligonucleotid
contain
cpgmotif
thigh
intraderm
id
experi
mice
anaesthetis
intraperiten
inject
ketaminexylazin
four
microlit
protein
andor
adjuv
andor
respect
adjuv
alon
pb
inject
id
ear
surgic
leica
microscop
leica
wetzlar
germani
use
ultrafin
syring
bd
bioscienc
describ
lin
et
tuberculosi
challeng
experi
six
week
final
vaccin
mice
infect
tuberculosi
via
aerosol
rout
use
middlebrook
airborn
infect
apparatu
glascol
infect
dose
approxim
viabl
bacilli
four
week
later
lung
spleen
harvest
homogen
plate
serial
dilut
supplement
middlebrook
agar
plate
coloni
form
unit
cfu
determin
approxim
week
later
express
cfu
histolog
analysi
middl
right
lobe
infect
mous
perfus
buffer
formalin
solut
tissu
sampl
embed
paraffin
thick
tissu
section
cut
stain
hematoxylin
eosin
h
e
slide
observ
leicadm
microscop
leica
microsystem
north
ryde
australia
magnif
acquir
mosaic
pbmc
isol
gradient
centrifug
approxim
blood
per
mous
sigma
accord
manufactur
instruct
splenocyt
auricular
lymph
node
mln
prepar
vaccin
infect
mice
passag
cell
strainer
bd
dorsal
ventral
pinna
separ
use
tweezer
cell
ear
dissoci
collagenas
mg
worthington
lakewood
nj
dnase
u
worthington
passag
cell
strainer
cell
resuspend
buffer
ammonium
sulfat
ack
buffer
mm
edta
sigma
mm
sigma
mm
sigma
lyse
erythrocyt
wash
resuspend
rpmi
life
technolog
supplement
heatinactiv
fetal
bovin
serum
scientifix
cheltenham
australia
sigma
u
penicillinstreptomycin
sigma
antigen
specif
produc
cell
detect
elispot
assay
describ
antigen
use
concentr
cytokin
elisa
cell
stimul
antigen
supernat
collect
hour
tnf
detect
describ
cytokin
assess
id
vaccin
ear
cell
suspens
cultur
hour
complet
rpmi
cell
supernat
frozen
use
cytokin
concentr
tnf
determin
use
cytokin
bead
array
bd
follow
manufactur
instruct
data
acquir
bd
lsrfortessa
flow
cytomet
bd
analyz
use
fcap
array
softwar
bd
usa
adopt
transfer
studi
transgen
tcr
mice
express
tcr
specif
residu
tuberculosi
protein
bred
hous
specif
pathogen
free
condit
splenocyt
prepar
label
cfse
mice
receiv
iv
cfse
label
splenocyt
next
day
immun
id
describ
previous
select
timepoint
ear
lymph
node
harvest
singl
cell
suspens
prepar
stain
flow
cytometri
see
intracellular
cytokin
stain
cell
stimul
hour
presenc
fusion
protein
hour
brefeldin
two
million
cell
incub
ebiosci
san
diego
ca
fac
wash
buffer
min
block
fc
receptor
wash
incub
min
either
clone
clone
apc
clone
fluorescein
isothiocyan
fitc
clone
bd
fixabl
blue
dead
cell
stain
life
technolog
ad
allow
dead
cell
discrimin
cell
fix
permeabil
use
bd
cytofixcytopermtm
kit
accord
manufactur
protocol
intracellular
stain
perform
use
follow
antibodi
pe
clone
antitnfapc
clone
biolegend
san
diego
ca
clone
bd
blue
clone
biolegend
surfac
stain
ear
sampl
prepar
cell
stain
bpe
clone
clone
clone
clone
anti
clone
clone
clone
clone
sampl
acquir
bd
lsrfortessa
flow
cytomet
bd
analyz
use
flowjotm
analysi
softwar
treestar
macintosh
version
ashland
boolean
combin
gate
use
calcul
frequenc
singl
doubl
tripleposit
cell
subset
pbmc
gate
strategi
intracellular
cytokin
stain
describ
ref
signific
differ
experiment
group
evalu
one
twoway
analysi
varianc
anova
pairwis
comparison
multigroup
data
set
achiev
use
tukey
dunnet
post
hoc
test
